

DAFTAR PUSTAKA

1. Fernanda MD. Blefaritis: Etiologi, Klasifikasi, Diagnosis, dan Tata Laksana. *CDK*. 2022;49(10):552–5.
2. Utami GADL. Diagnosis dan manajemen pada blefaritis anterior dan posterior. *Intisari Sains Medis*. 2021;12(1):262–8.
3. Viswambaran VK, K. A A, Chandrababu G, Babu A, Rajeev G, Gupta S. Blepharitis: A Review on Human Clinical Trials with Synthetic and Natural Remedies. *Biomedical and Pharmacology Journal*. 2020;13(4):1939–45.
4. Amescua G, Akpek EK, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK, et al. Blepharitis Preferred Practice Pattern®. *Ophthalmology*. 2019;126(1):P56–93.
5. Eberhardt M, Rammohan G. Blepharitis. *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459305/>
6. Guillon M, Maissa C, Wong S. Eyelid Margin Modification Associated With Eyelid Hygiene in Anterior Blepharitis and Meibomian Gland Dysfunction. *Eye & Contact Lens: Science & Clinical Practice*. 2012;38(5):319–25.
7. Lindsley K, Matsumura S, Hatf E, Akpek EK. Interventions for chronic blepharitis. *Cochrane Database of Systematic Reviews*. 2012;(5):8–10.
8. Dias MR, Guaresch BLV, Borges CR, Biazim DF, Casagrande DC, Luz RA. Blepharitis: Epidemiology, etiology, clinical presentations, treatment and evolution of our patients. *Rev Bras Oftalmol*. 2019;78(5):300–3.
9. Tehamen M, Rares L, Supit W. Gambaran Penderita Infeksi Mata di Rumah Sakit Mata Manado Provinsi Sulawesi Utara Periode Juni 2017 - Juni 2019. *e-CliniC*. 2019 Dec 31;8(1).
10. Putnam CM. Diagnosis and management of blepharitis: an optometrist's perspective. *Clin Optom (Auckl)*. 2016;8:71–8.
11. Bernardes TF, Bonfioli AA. Blepharitis. *Semin Ophthalmol*. 2010;25(3):79–83.
12. Musa A, Nazeerullah R, Sarite S. Bacterial profile and antimicrobial susceptibility pattern of anterior blepharitis in Misurata region, Libya. *Dentistry and Medical Research*. 2014;2(1):8.

13. Smolin G, Okumoto M. Staphylococcal Blepharitis. *Archives of Ophthalmology*. 1977;95(5):812–6.
14. Mashige KP. Ocular allergy. *Health SA Gesondheid*. 2017;22:113–21.
15. Bhandari V, Reddy J. Blepharitis: Always remember demodex. *Middle East Afr J Ophthalmol*. 2014;21(4):317.
16. Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. *Clin Optom (Auckl)*. 2018;Volume 10:57–63.
17. Gonzalez-Salinas R, Yeu E, Holdbrook M, Baba SN, Ceballos JC, Massaro-Corredor M, et al. Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study. *J Ophthalmol*. 2021;2021:1–7.
18. Liu S, Pavan-Langston D, Colby KA. Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes. *Ophthalmology*. 2012;119(10):2003–8.
19. Ficker L, Ramakrishnan M, Seal D, Wright P. Role of Cell-Mediated Immunity to Staphylococci in Blepharitis. *Am J Ophthalmol*. 1991 Apr;111(4):473–9.
20. Valenton MJ. Toxin-Producing Strains of *Staphylococcus epidermidis* (albus). *Archives of Ophthalmology*. 1973;89(3):186.
21. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. *British Journal of Ophthalmology*. 1984;68(8):524–8.
22. Kanski JJ, Bowling B. *Clinical Ophthalmology: A Systemic Approach* (Seventh Edition). Seventh Edition. New York: Elsevier Saunders; 2011. 34–39 p.
23. Skuta GL, Cantor LB, Cioffi GA, et al. American Academy of Ophthalmology Basic Clinical Science Course: External Disease and Cornea. *American Academy of Ophthalmology*. 2013;44–66.
24. Rodriguez-Garcia A, Babayan-Sosa A, Ramirez-Miranda A, Santa Cruz-Valdés C, Hernandez-Quintela E, Hernandez-Camarena JC, et al. A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel. *Clinical Ophthalmology*. 2022;Volume 16:1331–55.
25. Waghmare S V, Jeria S. A Review of Contact Lens-Related Risk Factors and Complications. Vol. 14, *Cureus*. 2022. p. e30118.

26. Kadri R, Tantry T, Parameshwar D, Kudva A, Achar A, Hegde S. Mascara induced milphosis, an etiological evaluation. *Int J Trichology*. 2013;5(3):144.
27. Amano S, Inoue K. Estimation of Prevalence of Meibomian Gland Dysfunction in Japan. *Cornea*. 2017;36(6):684–8.
28. Deepthi KG, Prabakaran SR. Ocular bacterial infections: Pathogenesis and diagnosis. *Microb Pathog*. 2020 Aug;145:104206.
29. AlDarrab A, Alrajeh M, Alsuhaibani AH. Meibography for eyes with posterior blepharitis. *Saudi Journal of Ophthalmology*. 2017;31(3):131–4.
30. Duncan K, Jeng BH. Medical management of blepharitis. *Curr Opin Ophthalmol*. 2015;26(4):289–94.
31. Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. *Clin Exp Optom*. 2011;94(2):200–6.
32. Torkildsen GL, Cockrum P, Meier E, Hammonds WM, Silverstein B, Silverstein S. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. *Curr Med Res Opin*. 2011;27(1):171–8.
33. Fadlallah A, Rami H El, Fahd D, Dunia I, Bejjani R, Chlela E, et al. Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. *Arq Bras Oftalmol*. 2012;75(3):178–82.
34. Pflugfelder SC, Karpecki PM, Perez VL. Treatment of Blepharitis: Recent Clinical Trials. *Ocul Surf*. 2014;12(4):273–84.
35. Chen M, Gong L, Sun X, Gu Y, He X, Qu J, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. *Curr Med Res Opin*. 2012;28(3):385–94.
36. Sung J, Wang MTM, Lee SH, Cheung IMY, Ismail S, Sherwin T, et al. Randomized double-masked trial of eyelid cleansing treatments for blepharitis. *Ocul Surf*. 2018;16(1):77–83.
37. Wladis EJ, Aakalu VK, Foster JA, Freitag SK, Sobel RK, Tao JP, et al. Intense Pulsed Light for Meibomian Gland Disease. *Ophthalmology*. 2020;127(9):1227–33.

38. Karthikeyan K, Kumar A. Madarosis: A marker of many Maladies. *Int J Trichology*. 2012;4(1):3.
39. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Definition and Classification Subcommittee. *Investigative Ophthalmology & Visual Science*. 2011 Mar 30;52(4):1930.
40. Lemp MA, Nichols KK. Blepharitis in the United States 2009: A Survey-based Perspective on Prevalence and Treatment. *Ocul Surf*. 2009 Apr;7(2):S1–14.
41. Angelika I, Rares F, Porotu'o J. Identifikasi bakteri aerob pada penderita infeksi mata luar di RSUD GMIM Pancaran Kasih Manado. *eBiomedik*. 2020;8(1):46–54.
42. Bukhari AA. Chronic Blepharitis . *Journal of King Abdulaziz University-Medical Sciences*. 2009;17(1):3–9.

